NCT00635232已完成2 期
A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 261
- 试验地点
- 40
- 主要终点
- Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
研究概览
简要总结
The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females 18 - 70 years
- •Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and < 180 mmHg and mean seated Diastolic Blood Pressure (DBP) > 90 and < 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
- •Women of child-bearing potential (WOCBP) must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year).
排除标准
- •Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases.
- •History of malignancy other than adequately treated basal cell or squamous cell skin cancer.
- •Subjects with a history of myocardial infarction or New York Heart Association (NYHA) class II-IV heart failure.
- •Subjects with a history of cerebrovascular accident or transient ischemic attack.
- •Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.
- •Subjects with hemodynamically significant valvular disease.
- •Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.
研究组 & 干预措施
Irbesartan 300mg
Active Comparator
Irbesartan 300 mg once daily
干预措施: irbesartan (Drug)
Placebo
Placebo Comparator
Blinded Placebo Treatment
干预措施: placebo (Drug)
PS433540 200mg
Experimental
PS433540 200mg once daily
干预措施: PS433540 (Drug)
PS433540 400mg
Experimental
PS433540 400mg once daily
干预措施: PS433540 (Drug)
PS433540 800mg
Experimental
PS433540 800mg once daily
干预措施: PS433540 (Drug)
结局指标
主要结局
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
时间窗: 12 weeks
次要结局
- Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.(12 weeks)
- The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.(12 weeks)
研究者
研究点 (40)
Loading locations...
相似试验
已完成
2 期
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionHypertensionNCT00522925Ligand Pharmaceuticals280
已完成
2 期
Safety Study of Anti-IgE Immunotherapy in Allergic PatientsAllergyNCT00439621Resistentia Pharmaceuticals AB42
终止
2 期
Maintaining Suppression of Testosterone With Transdermal Estradiol GelCancer of the ProstateNCT02349386BHR Pharma, LLC34
撤回
2 期
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsHIV InfectionsNCT00397566Bristol-Myers Squibb
已完成
2 期
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.Acute Non-cardioembolic Ischemic StrokeNCT04304508Bayer1,808